Related references
Note: Only part of the references are listed.Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies
Joel Rosenbloom et al.
ANNALS OF INTERNAL MEDICINE (2010)
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
John McHutchison et al.
GASTROENTEROLOGY (2010)
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Marie-Luise Berres et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment
Vivian Barry-Hamilton et al.
NATURE MEDICINE (2010)
Cellular and molecular mechanisms of fibrosis
T. A. Wynn
JOURNAL OF PATHOLOGY (2008)
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Adrian M. Di Bisceglie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
Paul J. Pockros et al.
HEPATOLOGY (2007)
Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC
Alaa Melhem et al.
JOURNAL OF HEPATOLOGY (2006)
The bone marrow functionally contributes to liver fibrosis
Francesco P. Russo et al.
GASTROENTEROLOGY (2006)
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing
C Morishima et al.
HEPATOLOGY (2006)
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners
S Radaeva et al.
GASTROENTEROLOGY (2006)
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect
DR Nelson et al.
HEPATOLOGY (2003)
Share Paper
